Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
該当なし
完了
NCT05323994
| 対象疾患 | Depression, COVID-19 |
|---|
| 相 | 該当なし |
|---|
| スポンサー | Servier Russia |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 104 名 |
|---|
| 開始日 | 2022年4月19日 |
|---|
| 完了日 | 2023年2月20日 |
|---|
| 結果公開日 | 2024年10月17日 |
|---|
概要
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks of treatment. 10 clinics and 10 of psychiatrists and neurologists across the country will participate in the study and it is estimated that each investigating physician will enroll 10 patients.
Antidepressive Effectiveness of Agomelatine in Patients With Depression Episode Occurred After COVID-19 Assessed by HAMD-17 After 8 Weeks of Treatment in the Daily Clinical Practice.
8 weeks · score on a scale
| Patients With Depression Occurred After COVID 19 | 10.9 ± 4.90 score on a scale |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。